TAE684 (NVP-TAE684)

For research use only.

Catalog No.S1108

63 publications

TAE684 (NVP-TAE684) Chemical Structure

CAS No. 761439-42-3

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR. TAE684 (NVP-TAE684) induces cell cycle arrest and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 269 In stock
USD 160 In stock
USD 290 In stock
USD 770 In stock
USD 1870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's TAE684 (NVP-TAE684) has been cited by 63 publications

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR. TAE684 (NVP-TAE684) induces cell cycle arrest and apoptosis.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMECwNFYxOyEQvF2= MofwV2FPT0WU
SF539 NHuxSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXGTWM2OD1yLkCwNFU3PCEQvF2= MoHCV2FPT0WU
DEL NVf1NWRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMECwPVI4KM7:TR?= M3O5NXNCVkeHUh?=
NB1 NInkU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnhTWM2OD1yLkCwNVYzKM7:TR?= M4CzOnNCVkeHUh?=
SR NWrobWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGyTWM2OD1yLkCwNlc4KM7:TR?= MVvTRW5ITVJ?
KARPAS-299 NFnROFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6cGtKSzVyPUCuNFI{QDRizszN M2jGXnNCVkeHUh?=
MHH-CALL-2 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEK5OVIh|ryP MWDTRW5ITVJ?
SU-DHL-1 NWLMd3ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13aN2lEPTB;MD6wOFg3PSEQvF2= M{T6SXNCVkeHUh?=
A4-Fuk M3zHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TIT2lEPTB;MD6wOVU3PSEQvF2= M1HuSHNCVkeHUh?=
EW-1 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\xZoFWUUN3ME2wMlExOjV4IN88US=> NX3DfHh[W0GQR1XS
NOS-1 NHn1XHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\kW2lEPTB;MD6xNFI6PCEQvF2= MkDSV2FPT0WU
EW-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXVbFFKSzVyPUCuNVA2PjhizszN M2LocHNCVkeHUh?=
TE-11 M1Lz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnyyTWM2OD1yLkG2NFk3KM7:TR?= MWPTRW5ITVJ?
SW982 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PZNGlEPTB;MD6xOlQ4QCEQvF2= M2H0PHNCVkeHUh?=
LAN-6 NUXi[o0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i0[mlEPTB;MD6xO|Q1OyEQvF2= NXjzS3JuW0GQR1XS
MZ1-PC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMUe4N|Uh|ryP NYGxdY1KW0GQR1XS
KS-1 NY\ve4F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H4[GlEPTB;MD6xPVM1OyEQvF2= MXHTRW5ITVJ?
PSN1 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjrbVVKSzVyPUCuNVk3OzFizszN MYnTRW5ITVJ?
LC-2-ad NGD6O4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofkTWM2OD1yLkG5OlkzKM7:TR?= MlTHV2FPT0WU
COLO-320-HSR NVW4b2pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\rRlg2UUN3ME2wMlE6Pzd4IN88US=> MnXDV2FPT0WU
OPM-2 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT5OItKSzVyPUCuNlI3PjlizszN MlXGV2FPT0WU
SK-NEP-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvVTWM2OD1yLkKzOVI1KM7:TR?= NHPhWI9USU6JRWK=
ALL-PO M3T0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXpTWM2OD1yLkK0OVI1KM7:TR?= MUjTRW5ITVJ?
CMK NGeyOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMkW1N{DPxE1? NYrlV5ZrW0GQR1XS
NCI-H1648 NI\FTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMke4OVUh|ryP NHj6SnJUSU6JRWK=
SIG-M5 NETHfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMkmxOVkh|ryP MlPqV2FPT0WU
TGBC24TKB NX;G[FF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnhV5BMUUN3ME2wMlMxOjF6IN88US=> MWTTRW5ITVJ?
DOHH-2 M2TwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf1cIl[UUN3ME2wMlMyOjB2IN88US=> NXLYbldXW0GQR1XS
NB69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInYc5dKSzVyPUCuN|E4QDdizszN MnixV2FPT0WU
MFH-ino NEPlNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfZcW1KSzVyPUCuN|I2OjNizszN MV3TRW5ITVJ?
KP-N-RT-BM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7uSmlmUUN3ME2wMlM{OTJ|IN88US=> Ml;TV2FPT0WU
MONO-MAC-6 NGHnXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHEfJpzUUN3ME2wMlM{OjlzIN88US=> MUPTRW5ITVJ?
ATN-1 NXLtOIh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vEPGlEPTB;MD6zN|MxOyEQvF2= NULPcnlxW0GQR1XS
NTERA-S-cl-D1 M1[3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDNO2hKSzVyPUCuN|M{QTZizszN NWLtXWJ4W0GQR1XS
L-540 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwM{[5PFgh|ryP NETwWVNUSU6JRWK=
GB-1 NU\yNFVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwM{i4Olch|ryP NWTXO3I{W0GQR1XS
MV-4-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwM{m0OFYh|ryP MkLBV2FPT0WU
KG-1 M2PBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHkb4NnUUN3ME2wMlM6PTZzIN88US=> NYLNT4FtW0GQR1XS
OVCAR-4 M2LDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX25R481UUN3ME2wMlQxPTZ7IN88US=> M3TyZXNCVkeHUh?=
NEC8 M2q2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;FVGlEPTB;MD60NVI6OiEQvF2= NEDVfnhUSU6JRWK=
SK-MM-2 M2e5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXsTWM2OD1yLkSxOlA6KM7:TR?= MkXKV2FPT0WU
TE-8 NXXhUolsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITmSIVKSzVyPUCuOFI5QCEQvF2= NFTOcJdUSU6JRWK=
697 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;1eFVFUUN3ME2wMlQ{OjF3IN88US=> MX3TRW5ITVJ?
NB14 NH;VUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\uTWM2OD1yLkSzPFI3KM7:TR?= MoD1V2FPT0WU
GDM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O4XWlEPTB;MD60O|EyPiEQvF2= NV3QO|RQW0GQR1XS
HUTU-80 NV\1NXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnTTWM2OD1yLkS3N|c2KM7:TR?= MofLV2FPT0WU
HL-60 M3PoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDoc2dKSzVyPUCuOFgyPDJizszN M4S4N3NCVkeHUh?=
OCI-AML2 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDBdXBVUUN3ME2wMlQ5OzJ6IN88US=> M175SHNCVkeHUh?=
ML-2 M4D6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL0TWM2OD1yLkS5NFMyKM7:TR?= M1z3VHNCVkeHUh?=
ES4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPGTWM2OD1yLkS5NVA6KM7:TR?= NXzuUIZvW0GQR1XS
NCI-H747 NF7sTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNEm4PUDPxE1? NELKeYtUSU6JRWK=
RL95-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDISoFKSzVyPUCuOVAyOTJizszN M2DBbHNCVkeHUh?=
TE-15 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LSTWlEPTB;MD61NVEzPCEQvF2= NEf5[otUSU6JRWK=
TE-12 NX3se2tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnryTWM2OD1yLkWzN|Q6KM7:TR?= M4fKSHNCVkeHUh?=
LB1047-RCC M33PPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17t[mlEPTB;MD61OFU1QSEQvF2= Mom5V2FPT0WU
LB831-BLC M3fFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\SeFlKSzVyPUCuOVUxOjNizszN NFLnN5RUSU6JRWK=
NCI-H1355 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi0VYNKSzVyPUCuOVUyQDRizszN NEDYbJNUSU6JRWK=
CTV-1 M{nSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j0NGlEPTB;MD61OVYzPCEQvF2= MlL5V2FPT0WU
RXF393 NYW2XYx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\DTWM2OD1yLkW1O|k1KM7:TR?= NXz6XZBWW0GQR1XS
SW872 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVznTYRxUUN3ME2wMlU3PzJ2IN88US=> M3vw[3NCVkeHUh?=
MPP-89 NH;n[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X0d2lEPTB;MD61O|g5PCEQvF2= MVnTRW5ITVJ?
RPMI-8226 NE\0eYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT6NJhKSzVyPUCuOlM2OjZizszN NEjrUGNUSU6JRWK=
LS-1034 NFnZPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi2TWM2OD1yLk[zOVgh|ryP NHX0UXRUSU6JRWK=
SJSA-1 NYHmV4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDRTWM2OD1yLk[zO|I2KM7:TR?= MkHGV2FPT0WU
HOP-62 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHDTWM2OD1yLk[1NFM{KM7:TR?= MoTQV2FPT0WU
KGN NV62Uop[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj0fHpKSzVyPUCuOlYyPjhizszN NVjkS5F7W0GQR1XS
D-336MG MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[xPWlEPTB;MD62OlE3QSEQvF2= MlTJV2FPT0WU
LS-411N MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy0V4VKSzVyPUCuOlc1PjJizszN MXjTRW5ITVJ?
TE-1 NWnuU2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HxeGlEPTB;MD62PVA4PCEQvF2= MWDTRW5ITVJ?
LB996-RCC M4LiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\4TWM2OD1yLk[5N|g6KM7:TR?= NFrUc2FUSU6JRWK=
TE-10 NYTuU3d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof1TWM2OD1yLkexOFk3KM7:TR?= M3HWW3NCVkeHUh?=
NCI-SNU-16 M{X0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzwTWM2OD1yLkeyOlY1KM7:TR?= NX7pNZF7W0GQR1XS
ES8 M1fqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTOW|dMUUN3ME2wMlc1QTd3IN88US=> MXrTRW5ITVJ?
COLO-800 NVT4bG14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO1TWM2OD1yLke2Olk2KM7:TR?= NW\5dXl6W0GQR1XS
ES6 NYHQVFl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjPT4pKSzVyPUCuO|c2PTlizszN MW\TRW5ITVJ?
L-363 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwOEKzO|Uh|ryP MV\TRW5ITVJ?
NMC-G1 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwOEOyN|Mh|ryP Mn3MV2FPT0WU
LU-134-A M{nVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwOEO5NVIh|ryP NIroVZNUSU6JRWK=
SF268 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r1fGlEPTB;MD64OFA1OiEQvF2= NFPXVGZUSU6JRWK=
KARPAS-45 NWjaT3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17obmlEPTB;MD64OFI3OyEQvF2= NVm4[|RXW0GQR1XS
TGW NYixNGoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkezTWM2OD1yLki1PFY{KM7:TR?= M3TJWXNCVkeHUh?=
CHP-126 NIjXOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HYOmlEPTB;MD64OVk2PyEQvF2= Mof2V2FPT0WU
MOLT-16 NVLDSFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\pVZdKSzVyPUCuPFc2QDlizszN NG[xdpRUSU6JRWK=
LB771-HNC NEPoS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwOEm3OVch|ryP MmrKV2FPT0WU
NALM-6 NVXYfGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwOUC3N|kh|ryP MXfTRW5ITVJ?
GCIY NXnCPVdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXEU5N7UUN3ME2wMlk2PTJ4IN88US=> Mlv5V2FPT0WU
IST-MES1 NXrtb2kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD1TFBRUUN3ME2wMlk5QDJ2IN88US=> MWPTRW5ITVJ?
LB2241-RCC Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwOUi4OEDPxE1? M2HmTHNCVkeHUh?=
BL-70 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3OTWM2OD1yLkm5OVM2KM7:TR?= NU\Y[5dxW0GQR1XS
NB17 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7rN2xKSzVyPUGuNFA3OzlizszN NX;h[HBlW0GQR1XS
LXF-289 M{TlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\vTWM2OD1zLkCzNFc3KM7:TR?= MV;TRW5ITVJ?
TK10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPOZYh6UUN3ME2xMlA2ODZ|IN88US=> NYHJdopqW0GQR1XS
K5 NGfDPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwME[yO|Qh|ryP MkTWV2FPT0WU
NCI-H716 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwMEeyOVkh|ryP MoDpV2FPT0WU
HCE-T M1nKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz5SVdLUUN3ME2xMlA5QDF7IN88US=> MWDTRW5ITVJ?
GI-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;ybWlEPTB;MT6wPVc6QCEQvF2= M{XDZ3NCVkeHUh?=
KARPAS-422 MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7zTWM2OD1zLkGwNFIzKM7:TR?= NFzqRZpUSU6JRWK=
TE-9 NHzOeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwMUGzNlgh|ryP NILhN3hUSU6JRWK=
SF126 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160XWlEPTB;MT6xNVU3QCEQvF2= NHPPdnhUSU6JRWK=
BB30-HNC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnkbVRGUUN3ME2xMlE{OTF{IN88US=> MULTRW5ITVJ?
NCI-H1304 NInId49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ns[GlEPTB;MT6xN|M{QCEQvF2= M3SyNXNCVkeHUh?=
HEL M3rQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPlSnJKSzVyPUGuNVQ5QTVizszN NVu2NXBKW0GQR1XS
HAL-01 NUm5coYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwMUWyPFMh|ryP MlnSV2FPT0WU
SK-LMS-1 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnHUoV1UUN3ME2xMlE2QTd2IN88US=> M1rnPXNCVkeHUh?=
SW954 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwMUm1Olch|ryP NYPqNGlkW0GQR1XS
D-283MED NWPQR3RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXNTWM2OD1zLkKyN|c6KM7:TR?= NGXGemNUSU6JRWK=
NCI-H1882 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\MTWM2OD1zLkKzPFkh|ryP M2fzW3NCVkeHUh?=
GI-ME-N NG\4R3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jWfGlEPTB;MT6yOVIxQCEQvF2= MkPVV2FPT0WU
SK-PN-DW NYGwbIx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfk[VdKSzVyPUGuNlY{PDhizszN M3\ocHNCVkeHUh?=
C2BBe1 M{T0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XJdGlEPTB;MT6yPVEyPyEQvF2= NFvPfINUSU6JRWK=
A704 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXOXHd5UUN3ME2xMlMzPjh7IN88US=> MkXkV2FPT0WU
KALS-1 NFvzbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwM{SwPEDPxE1? NGfjW5dUSU6JRWK=
ETK-1 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLUTWM2OD1zLkO0OFg6KM7:TR?= Mn7WV2FPT0WU
LB647-SCLC NU\2fW5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwM{S5PFYh|ryP NYe1fWdLW0GQR1XS
OCUB-M MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLlc5JKSzVyPUGuN|YyPDNizszN M1y4XnNCVkeHUh?=
NCI-H720 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXFTWM2OD1zLkO2N|c5KM7:TR?= MV7TRW5ITVJ?
NB13 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfSTWM2OD1zLkO3Nlk{KM7:TR?= MmnSV2FPT0WU
GR-ST MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwM{i3OVch|ryP Ml7XV2FPT0WU
DU-4475 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwNEW4OVMh|ryP M3\ZTHNCVkeHUh?=
HCC2157 NWTRZXRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwNE[2OVkh|ryP NYTI[FZTW0GQR1XS
RKO NUDPc3lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PvV2lEPTB;MT60PVkzOiEQvF2= MV3TRW5ITVJ?
LS-123 NHr4fIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L5WmlEPTB;MT61NVU6PCEQvF2= NV[0emdIW0GQR1XS
NCI-H69 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfNbVJKSzVyPUGuOVU5OTFizszN NYq2[opxW0GQR1XS
SW962 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP6XZZKSzVyPUGuOVYyOyEQvF2= MX;TRW5ITVJ?
PF-382 M1[2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXt[JpMUUN3ME2xMlU3QTZizszN NEe3c|ZUSU6JRWK=
A101D MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHWU3hKSzVyPUGuOVcyOTNizszN Mn3kV2FPT0WU
NB10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn3TWM2OD1zLkW3N|kzKM7:TR?= M3G3eXNCVkeHUh?=
NB5 NFr3O|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvQTWM2OD1zLkW4OFc3KM7:TR?= Mm\HV2FPT0WU
HCE-4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwNkC4OUDPxE1? MU\TRW5ITVJ?
HT-144 NUm3SW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwNkOxPUDPxE1? NGrIc|JUSU6JRWK=
NCI-H524 NWDQeXhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Cy[mlEPTB;MT62OFMxPyEQvF2= MY\TRW5ITVJ?
NKM-1 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jaR2lEPTB;MT62PFY3KM7:TR?= MXXTRW5ITVJ?
KURAMOCHI NYrZ[nE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi5RVlKSzVyPUGuOlk2PzNizszN NIGz[|ZUSU6JRWK=
NCI-H187 NFv1eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rGW2lEPTB;MT63NFA{PiEQvF2= MnfVV2FPT0WU
U-266 M1nIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi3[XZTUUN3ME2xMlc{QDR{IN88US=> NH20W5ZUSU6JRWK=
BL-41 M371VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHVT49KSzVyPUGuO|YzPzJizszN MV;TRW5ITVJ?
SK-N-DZ M1vmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PDZmlEPTB;MT63PFMxQSEQvF2= M1SzUnNCVkeHUh?=
Daudi MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwN{i5Olch|ryP M3v4N3NCVkeHUh?=
CPC-N NGrVVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvOXIhOUUN3ME2xMlg2ODl4IN88US=> M2XOb3NCVkeHUh?=
EM-2 M3\nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHxSIxKSzVyPUGuPFUyKM7:TR?= MVXTRW5ITVJ?
HCC1187 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLVd4JKSzVyPUGuPFYzPDFizszN MX7TRW5ITVJ?
LP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOydZNjUUN3ME2xMlg4OTR|IN88US=> M2GzWnNCVkeHUh?=
CAS-1 NXm2PXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnGZopxUUN3ME2xMlk5Ojl7IN88US=> NHTN[3RUSU6JRWK=
NB7 NGHVU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfnPHkyUUN3ME2yMlAxPTV3IN88US=> MXjTRW5ITVJ?
VA-ES-BJ MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV74eFlqUUN3ME2yMlAyPTF|IN88US=> Ml7CV2FPT0WU
SNU-C2B M{LPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PJSGlEPTB;Mj6wN|M2OSEQvF2= NXPrXpM{W0GQR1XS
LOXIMVI M3\ufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD6OI1zUUN3ME2yMlA3Pzh4IN88US=> Mmn5V2FPT0WU
NCI-H1581 M3;zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwMUG1OVkh|ryP Mn7mV2FPT0WU
IST-SL2 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorTTWM2OD1{LkGyOFQ2KM7:TR?= NELvOFhUSU6JRWK=
NOMO-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jxRWlEPTB;Mj6xO|Y5OyEQvF2= M4HzNHNCVkeHUh?=
TE-6 NXOxVFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwMUmwOUDPxE1? MlrNV2FPT0WU
NCI-H526 M1ixfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;ae2lEPTB;Mj6xPVE1OSEQvF2= Mn;uV2FPT0WU
MSTO-211H MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\5TWM2OD1{LkKwNFQyKM7:TR?= M3i5NnNCVkeHUh?=
LS-513 M{DIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHZNlNLUUN3ME2yMlIzOjZ7IN88US=> M2r6NHNCVkeHUh?=
NCI-SNU-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfrcoY1UUN3ME2yMlM{OjV4IN88US=> NIXoRpFUSU6JRWK=
BB65-RCC MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xt[mlEPTB;Mj6zO|Q6OyEQvF2= M4PuZXNCVkeHUh?=
GT3TKB NVzJOI5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwM{m5O|Ih|ryP NEjSSWJUSU6JRWK=
OS-RC-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37VSmlEPTB;Mj60NlM1OSEQvF2= NHrL[pdUSU6JRWK=
NCI-H2126 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnrTWM2OD1{LkSzOlc1KM7:TR?= MYDTRW5ITVJ?
SK-UT-1 M2HkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDLZY5KSzVyPUKuOFc1PjdizszN NEXZVZNUSU6JRWK=
DMS-114 NIDnOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfMXWRoUUN3ME2yMlYyPTJ2IN88US=> NHy1SpBUSU6JRWK=
ONS-76 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJwNkO2OFEh|ryP MoPaV2FPT0WU
8-MG-BA M3e3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfZRm46UUN3ME2yMlY2PDF2IN88US=> MXnTRW5ITVJ?
BOKU MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfzOIFlUUN3ME2yMlczPzZ2IN88US=> NYPtXG9UW0GQR1XS
LAMA-84 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwN{m5NVIh|ryP NG\vNo1USU6JRWK=
ES1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJwOEG4NFQh|ryP NVu1b4Z5W0GQR1XS
NCI-H1395 NET6cVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfKTWM2OD1{LkiyNFEzKM7:TR?= MXLTRW5ITVJ?
A388 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLYTWM2OD1{Lkm2NVch|ryP NV7jZ|Z1W0GQR1XS
NCCIT NY\6dHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwMEi4OlIh|ryP NEfB[|RUSU6JRWK=
HD-MY-Z MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwMUOyNFMh|ryP Ml[1V2FPT0WU
NCI-H510A M{L2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPdoJMUUN3ME2zMlE5QTR|IN88US=> NETie2tUSU6JRWK=
NCI-N87 NUXneYlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnOUJNKSzVyPUOuNlAxOiEQvF2= MWTTRW5ITVJ?
SCLC-21H MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HuTWlEPTB;Mz6yOlg2QSEQvF2= NFTJWnlUSU6JRWK=
SH-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwMki3PVch|ryP NUT2U|ZxW0GQR1XS
QIMR-WIL NG\SN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS5TWM2OD1|LkOyPFQ6KM7:TR?= MW\TRW5ITVJ?
KM12 NX;VZ2NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwM{O1OFQh|ryP MXLTRW5ITVJ?
ST486 NWrlc|hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjDTWM2OD1|LkWzPFg{KM7:TR?= MnzWV2FPT0WU
HC-1 NHLEWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xv[GlEPTB;Mz62NlAzQCEQvF2= M3jxTnNCVkeHUh?=
BV-173 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzaSm9KSzVyPUOuOlQxQDhizszN M2HQTnNCVkeHUh?=
EW-24 M2W4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwNk[0N|Qh|ryP NF7nNnRUSU6JRWK=
LU-65 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyyT2QzUUN3ME2zMlY5PzFizszN M2jnXnNCVkeHUh?=
ECC4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNwN{e1OkDPxE1? M2LoW3NCVkeHUh?=
ARH-77 NITRXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmyWlN1UUN3ME20MlEyODZ5IN88US=> NXPwTIN[W0GQR1XS
BC-3 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRwMUOwOlgh|ryP NE[5bIZUSU6JRWK=
SNB75 M1ywRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRwMk[xPUDPxE1? M3;FTXNCVkeHUh?=
MEG-01 Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j0SWlEPTB;ND6yO|QyQSEQvF2= MmLtV2FPT0WU
NCI-H1417 M2OxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rObWlEPTB;ND6yPFQ1OyEQvF2= NI\lPZVUSU6JRWK=
MDA-MB-134-VI M1LZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\JUpNKSzVyPUSuN|A3ODFizszN MkfOV2FPT0WU
Becker M17r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\2TWM2OD12LkS3N|M3KM7:TR?= NFHvdlVUSU6JRWK=
DMS-153 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDnTWM2OD12Lk[2OFc2KM7:TR?= MVTTRW5ITVJ?
TGBC1TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:4dnZWUUN3ME20MlY5PTF3IN88US=> MmDzV2FPT0WU
EW-3 NV;nVllnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwN{[yOFgh|ryP NFHlVlFUSU6JRWK=
KE-37 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[x[lFKSzVyPUSuPFYyQTZizszN NWeyc3h7W0GQR1XS
NCI-H23 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn4cWN7UUN3ME20Mlg4OjJ5IN88US=> MVHTRW5ITVJ?
MC116 NYjCOmtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHUTWM2OD12Lkm0NVI3KM7:TR?= NH3UR3JUSU6JRWK=
NH-12 M1X6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33rSGlEPTB;ND65OlQ{QSEQvF2= NVzLZ4g2W0GQR1XS
CTB-1 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLuW5NNUUN3ME20Mlk4PzJzIN88US=> MWLTRW5ITVJ?
KM-H2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\oeHpKSzVyPUWuNFU{OjNizszN NHHhSJNUSU6JRWK=
MOLT-4 NHXwSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWriXHQ4UUN3ME21MlEyQDNizszN NWryfWI3W0GQR1XS
NCI-H2141 NUW4[5o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL5TWM2OD13LkG0NlY5KM7:TR?= M2G5NHNCVkeHUh?=
EB-3 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvOWHg1UUN3ME21MlE4PTB2IN88US=> NXyzb5ZDW0GQR1XS
NCI-H1522 NWK5N|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;iUmlEPTB;NT6yOlMzOiEQvF2= MkDMV2FPT0WU
MRK-nu-1 NFOyfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rDWmlEPTB;NT60N|Y{OyEQvF2= MXnTRW5ITVJ?
no-11 M2XCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfOUY9rUUN3ME21MlQ4ODh5IN88US=> NVnXcppEW0GQR1XS
CESS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjlUmloUUN3ME21MlU5ODN2IN88US=> MYfTRW5ITVJ?
KMOE-2 NVLhU|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXOTWM2OD13LkW4OlU6KM7:TR?= M4nXSXNCVkeHUh?=
REH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHztVWZKSzVyPU[uNlU3OThizszN NGr2UolUSU6JRWK=
KU812 MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\lTWM2OD14LkSyO|kyKM7:TR?= MYjTRW5ITVJ?
SK-N-FI MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HDeGlEPTB;Nj62NFY4PCEQvF2= NFLnRZpUSU6JRWK=
MMAC-SF MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHWcXpKSzVyPUeuNFY1QTJizszN MX3TRW5ITVJ?
RCC10RGB MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jjXWlEPTB;Nz6yNlk4PyEQvF2= MkHlV2FPT0WU
NCI-H322M MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorFTWM2OD15LkOzN|M2KM7:TR?= MW\TRW5ITVJ?
NB6 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq2dHF7UUN3ME23MlU1QDl7IN88US=> M{HLfXNCVkeHUh?=
MN-60 NWnWOok4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDDd|NKSzVyPUeuOlkzOTVizszN NWnVUYU1W0GQR1XS
NCI-H1092 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwMEG3N|Qh|ryP NULPRXV{W0GQR1XS
EKVX MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17jfmlEPTB;OD60O|A3PiEQvF2= MYDTRW5ITVJ?
D-263MG MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRThwNUWzPVYh|ryP NEX5TVRUSU6JRWK=
NCI-H209 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3XOFBKSzVyPUiuOlQxODZizszN NFrzVG1USU6JRWK=
IST-SL1 M4H2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRThwOEm4PVIh|ryP Ml;SV2FPT0WU
ACN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknDTWM2OD17LkG5NVU4KM7:TR?= M2TLVnNCVkeHUh?=
MHH-PREB-1 NGrLVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr0cGpoUUN3ME25MlIyOjF7IN88US=> NIOxWmtUSU6JRWK=
EW-11 M3u4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\nTWM2OD17Lk[1N|k3KM7:TR?= M1j6XHNCVkeHUh?=
KASUMI-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTlwN{i3O{DPxE1? M2DyZnNCVkeHUh?=
KINGS-1 NWLnc2t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHYTWM2OD1zMD6yN|Q4KM7:TR?= Ml\QV2FPT0WU
EVSA-T NGC0OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjBXm1XUUN3ME2xNE4{OTl{IN88US=> Mn64V2FPT0WU
DSH1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrxTWM2OD1zMD6zPVczKM7:TR?= MVTTRW5ITVJ?
COLO-824 NHTycI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD1zMD64OlY6KM7:TR?= Moe4V2FPT0WU
K052 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFyLkmzNlIh|ryP MULTRW5ITVJ?
SK-MEL-2 NG\ad|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET5PWlKSzVyPUGwMlk6OzlizszN MVvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ALK / ALK / p-STAT3 / STAT3 / p-ERK / ERK / p-AKT / AKT / Survivin / BIM / PARP ; 

PubMed: 22240786     


H3122 or H2228 cells were incubated with the indicated concentrations of TAE684 for 48 h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to phosphorylated (p) or total forms of ALK, STAT3, ERK, or AKT as well as with those to BIM, to survivin, to PARP, or to β-actin (loading control). The positions of the bands for EML4–ALK, BIMEL, and intact and cleaved forms of PARP are shown for the corresponding antibodies. 

p-ROS1 / ROS1 ; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various identified ROS1 inhibitors selected from the high throughput screening. CD74-ROS1-WT-expressing (clone 6) or CD74-ROS1-G2032R-expressing Ba/F3 cells were exposed to increasing concentrations of cabozantinib (XL184), TAE684, or foretinib (B) for 2 h. Following treatment, the cell lysates were immunoblotted to detect the indicated proteins.

22240786 25351743
Growth inhibition assay
Cell viability; 

PubMed: 18594010     


NSCLC cells were treated with TAE-684 at the indicated concentrations, and viable cells were measured after 72 hours of treatment. The percentage of viable cells is shown relative to untreated controls. A549 (KRAS G12S); PC9 (EGFRdelE746_A750); H2228 (EML4-ALK variant 3); H3122 (EML4-ALK variant 1); DFCI032 (EML4-ALK variant 1). 

18594010
In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research:[1]
- Collapse
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 4
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID